Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2025)

Innate Pharma (IPHA) has reported Long-Term Debt Repayments for 7 consecutive years, with -$10.1 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Debt Repayments changed 0.28% year-over-year to -$10.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.0 million (down 42.27% YoY) and the FY2025 annual result came in at -$10.1 million, changed 0.28% from the prior year.
• Long-Term Debt Repayments steadied at -$10.1 million in Q4 2025 per IPHA's latest filing, from -$10.2 million in the prior quarter.
• Over the last five years, Long-Term Debt Repayments for IPHA reached as high as -$1.1 million in Q2 2022 and fell as low as -$10.2 million in Q4 2024.
• A 5-year average of -$4.1 million and a median of -$2.4 million in 2021 frame the typical range for Long-Term Debt Repayments.
• Annual changes were most pronounced in 2022 — Long-Term Debt Repayments grew 15.0% — and 2024, when it sank 278.48%.
• Year by year, Long-Term Debt Repayments stood at -$2.4 million in 2021, then climbed by 2.08% to -$2.3 million in 2022, then declined by 16.54% to -$2.7 million in 2023, then plunged by 278.48% to -$10.2 million in 2024, then rose by 0.28% to -$10.1 million in 2025.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$10.1 million, -$10.2 million, and -$5.0 million for Q4 2025, Q4 2024, and Q2 2024 respectively.